TG Therapeutics Inc. Common Stock (TGTX)
Stock · NASDAQ · Health Care
$54.03as of 10/16/2026
Price chart
Active signals
TGTX Signal Track Record
How signals performed across all stocks →What TGTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -0.1% | 49% | September 16, 2026 |
| Bollinger Band Breakout | 30 | +2.3% | 57% | June 9, 2026 |
| Bollinger Band Breakdown | 18 | +11.8% | 67% | August 4, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -5.4% | 30% | March 26, 2026 |
| Any 20-session window (baseline) | +2.3% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsin…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 399
- Website
- www.tgtherapeutics.com/
Fundamentals
- 1-day range
- $53.66$56.25
- Market cap
- $7.59B
- P/E (trailing)
- 19.42
- P/E (forward)
- 19.93
- EPS (trailing)
- $2.75
- Dividend yield
- —
- Beta
- 1.82
- Avg. volume
- 1.97M
How TG Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
TG Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TGTXTG Therapeutics Inc. Common Stock$53.97▼ 3.62%Market cap $7.59BP/E 19.42$26.76$59.3
- RYTMRhythm Pharmaceuticals Inc. Common Stock$86.17▼ 2.05%Market cap $7.72BP/E —$74.5$122.2
- LQDALiquidia Corporation Common Stock$34.35▼ 1.24%Market cap $7.95BP/E 22.46$21.94$93.61
- COGTCogent Biosciences Inc. Common Stock$29.52▲ 0.03%Market cap $7.14BP/E —$13.78$43.73
- ALKSAlkermes plc Ordinary Shares$41.22▲ 2.79%Market cap $8.11BP/E 99.15$27$55.67
- BLTEBelite Bio Inc American Depositary Shares$142.78▼ 6.45%Market cap $6.32BP/E —$78.71$200
- ERASErasca Inc. Common Stock$13.39▼ 9.95%Market cap $6.25BP/E —$2.11$24.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TGTX TG Therapeutics Inc. Common Stock | $7.59B | 19.42 | $53.97 | ▼ 3.62% | $26.76$59.3 |
| RYTM Rhythm Pharmaceuticals Inc. Common Stock | $7.72B | — | $86.17 | ▼ 2.05% | $74.5$122.2 |
| LQDA Liquidia Corporation Common Stock | $7.95B | 22.46 | $34.35 | ▼ 1.24% | $21.94$93.61 |
| COGT Cogent Biosciences Inc. Common Stock | $7.14B | — | $29.52 | ▲ 0.03% | $13.78$43.73 |
| ALKS Alkermes plc Ordinary Shares | $8.11B | 99.15 | $41.22 | ▲ 2.79% | $27$55.67 |
| BLTE Belite Bio Inc American Depositary Shares | $6.32B | — | $142.78 | ▼ 6.45% | $78.71$200 |
| ERAS Erasca Inc. Common Stock | $6.25B | — | $13.39 | ▼ 9.95% | $2.11$24.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TG Therapeutics Says BRIUMVI Showed 44% Lower Risk Of MS Disability Progression vs. Ocrelizumab, 49% vs. Ofatumumab In Indirect Comparisonbenzinga · 10/12/2026
- How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment StoryYahoo · 10/9/2026
- TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh NewsflowYahoo · 10/9/2026
- TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026Yahoo · 10/8/2026
- TG Therapeutics (NASDAQ:TGTX) Emerges as an Affordable Growth Play in BiotechChartMill · 10/5/2026
- Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts ApproachBenzinga · 9/25/2026
- Novo Nordisk: Capital Markets Day Reveals Its Next Growth EngineSeekingAlpha · 9/24/2026
- Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy SignalsYahoo · 9/23/2026
- Dow Jones Futures: Nasdaq Hits New High; Sandisk, Micron Trigger Buy SignalsYahoo · 9/23/2026
Insider Activity
Insider Actions →- Charney Laurence N · September 10, 2026 · Sale5.0K @ $54.96
- Charney Laurence N · August 7, 2026 · Gift450
- Charney Laurence N · August 7, 2026 · Gift500
- Charney Laurence N · August 6, 2026 · Gift5.1K
- Charney Laurence N · June 11, 2026 · Grant8.3K
- HUME DANIEL · June 11, 2026 · Grant8.3K
- Hoberman Kenneth · June 11, 2026 · Grant8.3K
- Echelard Yann · June 11, 2026 · Grant8.3K
- Lonial Sagar · June 11, 2026 · Grant8.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 99.97M
- Total value held
- $3.26B
- Institutional holders
- 355
- Unknown22.25M
- Unknown8.65M
- Unknown6.60M
- Unknown4.03M
- Unknown3.50M
- Unknown3.21M
- Unknown3.15M
- Unknown3.08M
- Unknown2.44M
- Unknown2.17M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
TGTX Highlighted as Affordable Biotech Growth Play
ChartMill recently featured TG Therapeutics as an affordable growth option within the biotech sector. This analysis suggests the stock may be viewed as undervalued relative to its potential, despite trading near its 52-week low. The mention adds a positive fundamental perspective to the current technical setup.
TGTX Highlighted as Affordable Biotech Growth Play. ChartMill recently featured TG Therapeutics as an affordable growth option within the biotech sector. This analysis suggests the stock may be viewed as undervalued relative to its potential, despite trading near its 52-week low. The mention adds a positive fundamental perspective to the current technical setup.